A new algorithm to convert a normal antibody into the corresponding catalytic antibody.

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Thousands of monoclonal antibodies (mAbs) exist, with potential for catalytic applications.
• Converting mAbs into catalytic antibodies could offer significant scientific and therapeutic value.

Purpose of the Study:

• To develop a system for converting monoclonal antibodies into catalytic antibodies.
• To investigate the role of Proline 95 (Pro⁹⁵) in antibody light chain catalytic function.

Main Methods:

• Designed a system to delete Pro⁹⁵, a conserved residue in the CDR-3 of antibody light chains.
• Compared the catalytic activity of antibody light chains with and without Pro⁹⁵.
• Tested enzymatic degradation of peptide substrates and amyloid-beta molecules.

Main Results:

• Deletion of Pro⁹⁵ in S35 and T99wt light chains conferred peptidase activity.
• Antibody light chains retaining Pro⁹⁵ showed no or minimal catalytic activity.
• Pro⁹⁵-deleted mutants enzymatically degraded peptide substrates and amyloid-beta.

Conclusions:

• The deletion of Pro⁹⁵ is a key factor enabling catalytic function in antibody light chains.
• This finding presents a novel strategy for generating catalytic antibodies from existing monoclonal antibodies.
• The engineered catalytic antibodies show potential for degrading specific peptide substrates, including amyloid-beta.